里昂发表研究报告指，和黄医药(00013.HK) 去年肿瘤科产品销售按年升65%，纯利达3,800万美元，胜于预期。集团渠道更新符合该行预期，其中脾酪氨酸激酶(Syk)批准、赛沃替尼(savolitinib)在美国的新药申请、近期SAVANNAH研究数据结果，均是值得关注。
该行表示，将公司今年及明年收入预测分别降25%及28%，而各年纯利预测则分别上调12.8%及4.3%，同时将其目标价由27.1元上调至30.7元，维持其评级为“跑赢大市”。(ca/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-20 12:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.